ERBB2 and breast cancer: This may indicate that our analysis of lesion distribution and internal enhancement patterns was insufficient to distinguish HER2-low breast cancer, and more refined analyses, such as those for quantitative features, are needed to better differentiate HER2-low breast cancer in NME lesions.